Bio Solution Receives MFDS Approval for Phase 1/2a Clinical Trial of Allogeneic Chondrocyte Spheroid Sperocure for Knee Osteoarthritis
The Ministry of Food and Drug Safety MFDS approved Bio Solution's Phase 1/2a clinical trial plan for allogeneic chondrocyte spheroid Sperocure on July 13, 2026, approximately eight months after the application in November 2025.
The trial evaluates safety and efficacy in knee osteoarthritis patients, consisting of Phase I dose escalation and Phase IIa placebo-controlled double-blind design. Target enrollment is up to 18 patients for Phase I and 41 to 68 for Phase IIa, with expected completion in January 2029.
This clinical trial approval represents an early stage of drug development with a statistical probability of final approval around 10%. This disclosure does not involve capital changes or shareholder return policies.
[AI Summary]Bio Solution progressed its key pipeline Sperocure to clinical Phase 1/2a approval, marking a step forward in new drug development. While short-term financial impact is limited, success could significantly enhance long-term enterprise value. Investors should consider the inherent uncertainties and high failure rate of clinical trials.
KOSDAQ Filing Information
Major Management Matters Related to Investment Judgment (Decision on Approval of Clinical Trial Plan Application, etc.) (Approval of Phase 1/2a Clinical Trial Plan for Allogeneic Chondrocyte Spheroid (SpheroCure))